LAG-3 Antagonist Melanoma Treatment
Summary
The USPTO published patent application US20260109766A1 for LAG-3 antagonist therapy for treating melanoma, filed September 12, 2025 by inventors Shivani SRIVASTAVA and Mena ABASKHAROUN. The application covers methods of treating unresectable or metastatic melanoma using a LAG-3 antagonist, optionally in combination with a CTLA-4 inhibitor and/or additional anti-cancer therapies.
“The disclosure provides a method of treating unresectable or metastatic melanoma in a human patient with a lymphocyte activation gene-3 (LAG-3) antagonist.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 223 changes logged to date.
What changed
The USPTO published a new patent application (US20260109766A1) covering methods of treating unresectable or metastatic melanoma using a lymphocyte activation gene-3 (LAG-3) antagonist, including combination regimens with CTLA-4 inhibitors and additional anti-cancer therapies. The application was filed September 12, 2025.
For pharmaceutical and biotech companies engaged in immuno-oncology research, this publication signals potential competitive developments in the LAG-3/immune checkpoint space for melanoma. As a patent application publication, this document does not create compliance obligations; however, freedom-to-operate analysis may become relevant if any entity advances LAG-3 antagonist programs toward commercialization.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LAG-3 ANTAGONIST THERAPY FOR MELANOMA
Application US20260109766A1 Kind: A1 Apr 23, 2026
Inventors
Shivani SRIVASTAVA, Mena ABASKHAROUN
Abstract
The disclosure provides a method of treating unresectable or metastatic melanoma in a human patient with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method includes a combination of the LAG-3 antagonist with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor. In some aspects, the method includes one or more additional therapeutic agents and/or anti-cancer therapies.
CPC Classifications
C07K 16/2803 A61K 39/3955 A61P 17/00 A61P 35/00 A61P 35/04 C07K 16/2818 C07K 16/2827 A61K 2039/507 A61K 2039/54 A61K 2039/545 C07K 2317/21 C07K 2317/565 C07K 2317/90 C07K 2317/94 C07K 2319/00
Filing Date
2025-09-12
Application No.
19327078
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.